Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Photosensitiser in the photodynamic therapy of neovascular age-related macular degeneration Age: Adult |
Dose: Intravenous – 6 mg/m2 Frequency: infusion over 10 minutes, followed by activation using a laser tuned to a wavelength of 689 nm 15 minutes after the start of the infusion Duration: Repeat every 3 months for recurrent choroidal neovascular leakage Note: Recommended light dose is 50J/cm2, given over 83 seconds. |
|
Indication: Photosensitiser in the photodynamic therapy of neovascular age-related macular degeneration Condition: Hepatic impairment: Biliary obstruction; moderate to severe impairment |
Dose: Intravenous – 6 mg/m2 Note: Use with caution as no studies done. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: Not recommended |
Administration
- Given by IV infusion
- Eye drops used after infusion
Side Effect
- Visual disturbances
- severe vision loss with or without subretinal or vitreous bleeding
- Injection site reactions
- nausea
- photosensitivity
- asthenia
- cataracts
- blepharitis
- conjunctivitis
- dry eyes
- ocular itching
- flu-like syndrome
- atrial fibrillation
- hypertension
- peripheral vascular disorder
- varicose veins
- eczema
- constipation
- GI cancers
- fever
- lachrymation disorder
- hypersensitivity reactions
- increased LFT
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Calcium Channel Blockers (Amlodipine, Diltiazem, Verapamil, Nifedipine, Felodipine, Nicardipine, Isradipine), Polymyxin B, Radiation therapy
|
Increased rate of verteporfin uptake by the vascular endothelium
|
|
Photosensitizing Agents (Methoxsalen, Verteporfin)
|
Increased photosensitivity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Porphyria
|
Risk of acute attacks
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.